print this page

Clinical Trials: Children's Health


A Randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intra-abdominal infection (IRB# BH-10-113)

(Children's health, Surgery)
  • Principal Investor
    Patrick Lee, MD
  • Summary

    The purpose of this study is to find out if an antibiotic currently being given to adults, moxifloxacin, is safe and effective for children with complicated infections in the abdomen.  Participants in this trial will receive either moxifloxacin or ertapenem followed by amoxicillin/clavulanate orally.

  • More Information

    Eligibility:

    To participate in this trial, you must be age 6-17 and have a complicated intra-abdominal infection such as a burst appendix.

  • Study Site Location
    Baystate Medical Center
  • Contact
    Barbara Burkott, RN, BSN, CCRP
    413-794-1305
    Email

Children’s Arthritis & Rheumatology Research Network (CARRANet): Accelerating Toward an Evidence Based Culture in Pediatric Rheumatology (IRB# 167921)

(Children's Health)
  • Principal Investor
    Peter Blier, MD, PhD
  • Summary

    The CARRANet Research Registry was created to improve outcomes and quality of life for all children through clinical and translational research. The CARRANet Registry will create a database for rheumatic diseases of childhood including but not limited to: Systemic Lupus Erythematosus (SLE) Juvenile Idiopathic Arthritis/Juvenile Rheumatoid Arthritis (JIA) , Juvenile Dermatomyositis (JDM), Juvenile Primary Fibromyalgia Syndrome (JPFS), and Localized Scleroderma (LS).

  • More Information

    Eligibility: 

    Onset of rheumatic disease prior to age 16 for JIA and prior to age 18 for all other rheumatic diseases.  

  • Study Site Location
    Baystate Pediatric Rheumatology, 3300 Main St. Springfield MA
  • Contact
    Mary Gervasini, BA, CCRP
    413.794.4158
    Email

MEM-MD 91 An Open-label study of the safety and tolerability of Memantine in Pediatric patients(6-12 y.o.) with Autism, AspergersDisorder or Pervasive Deveopmental Disorder Not otherwise Specified. (IRB# 338277-11)

(Children's health, Mental health)
  • Principal Investor
    Bruce Waslick, MD
  • Summary

    The purpose of this study is to evaluate the safety and tolerability of memantine in pediatric (6-12 years old) patients with autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).  

  • More Information

    Eligibility

    Must be between the ages of 6-12 and meet the criteria for diagnosis of autism, Asperger’s Disorder or Pervasive Developmental Disorder not otherwise specified.  

  • Study Site Location
    3300 Main Street, Springfield, MA
  • Contact
    Julie Kingsbury
    413.794.1136
    Email